SCHEMBL32677166

SCHEMBL32677166

Cc1nonc1CC(=O)N1CCC(c2nc(-c3ccc(F)cc3C(F)(F)F)no2)CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
CNR2 P34972 2/20 0.48
EPHX1 P07099 1/20 0.47
CYP2C9 P11712 1/20 0.47
EPHX2 P34913 1/20 0.47
KCNH2 Q12809 1/20 0.47
CACNA1C Q13936 1/20 0.47
CNR1 P21554 1/20 0.45
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
RECQL P46063 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32676709 0.90 LMNA (0.54) LMNAALOX15TSHRMAPK1MEN1
SCHEMBL30730519 0.88 TSHR (0.52) LMNAALOX15TSHRMAPK1CNR2
SCHEMBL32676612 0.85 LMNA (0.53) LMNAALOX15TSHRMAPK1MEN1
SCHEMBL32676848 0.85 LMNA (0.53) LMNAALOX15TSHRMAPK1MEN1
SCHEMBL30730662 0.84 LMNA (0.71) LMNAALOX15TSHRMAPK1MEN1
SCHEMBL30730433 0.83 LMNA (0.48) LMNAALOX15TSHRMAPK1MEN1
SCHEMBL30730483 0.82 LMNA (0.58) LMNAALOX15TSHRMAPK1
SCHEMBL32676698 0.82 LMNA (0.50) LMNAALOX15TSHRMAPK1CNR2
SCHEMBL30730665 0.82 TSHR (0.55) LMNAALOX15TSHRMAPK1CNR2
SCHEMBL30730505 0.82 LMNA (0.51) LMNAALOX15TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 LMNA 1838/4885ALOX15 2647/4885TSHR 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.